Oak Ridge Investments LLC Sells 2,433 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Oak Ridge Investments LLC lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.9% in the third quarter, Holdings Channel reports. The institutional investor owned 60,340 shares of the biopharmaceutical company’s stock after selling 2,433 shares during the period. Oak Ridge Investments LLC’s holdings in Halozyme Therapeutics were worth $3,454,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Congress Asset Management Co. lifted its position in shares of Halozyme Therapeutics by 446.5% in the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after acquiring an additional 1,988,238 shares during the period. Meitav Investment House Ltd. acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at $3,606,000. Diversify Wealth Management LLC lifted its position in Halozyme Therapeutics by 28.8% in the third quarter. Diversify Wealth Management LLC now owns 9,439 shares of the biopharmaceutical company’s stock worth $540,000 after purchasing an additional 2,108 shares during the period. New York State Teachers Retirement System increased its holdings in Halozyme Therapeutics by 12.8% in the 3rd quarter. New York State Teachers Retirement System now owns 127,327 shares of the biopharmaceutical company’s stock valued at $7,288,000 after buying an additional 14,489 shares during the period. Finally, Davidson Capital Management Inc. increased its holdings in Halozyme Therapeutics by 14,012.1% in the 3rd quarter. Davidson Capital Management Inc. now owns 26,813 shares of the biopharmaceutical company’s stock valued at $1,535,000 after buying an additional 26,623 shares during the period. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of HALO stock opened at $50.57 on Friday. Halozyme Therapeutics, Inc. has a 52 week low of $33.07 and a 52 week high of $65.53. The stock has a market capitalization of $6.41 billion, a PE ratio of 19.60, a PEG ratio of 0.49 and a beta of 1.27. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41. The stock’s fifty day moving average is $57.32 and its 200-day moving average is $51.82.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The firm had revenue of $231.40 million for the quarter, compared to analyst estimates of $204.94 million. During the same quarter in the prior year, the firm earned $0.68 EPS. The company’s revenue was up 4.7% on a year-over-year basis. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total transaction of $592,000.00. Following the transaction, the chief executive officer now owns 676,744 shares of the company’s stock, valued at approximately $40,063,244.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total value of $570,133.70. Following the transaction, the director now owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total transaction of $592,000.00. Following the sale, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at approximately $40,063,244.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 89,881 shares of company stock valued at $5,169,834 over the last quarter. Corporate insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on HALO. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Morgan Stanley upped their price objective on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. TD Cowen raised their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price target on shares of Halozyme Therapeutics in a research note on Friday, October 25th. Finally, Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $60.44.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.